Orelabrutinib must be administered in strict compliance with the doctor’s instructions, with special attention paid to contraindications, dosage adjustment, adverse reaction monitoring, and drug interactions. As a prescription-only medicine, it is primarily indicated for the treatment of specific B-cell lymphomas. Its use must be standardized based on the patient’s condition, physical constitution, and test results, and the dosage must not be increased, decreased, or discontinued without medical approval.
I. Precautions Before Medication
Contraindications and Allergy History
Orelabrutinib is contraindicated in patients hypersensitive to any of its ingredients. Patients with severe hepatic or renal insufficiency, active bleeding, arrhythmia, or a history of immune system disorders must inform the doctor in advance.
Pregnancy and Lactation
This drug may cause harm to the fetus. Strict contraception should be practiced during the treatment period. Lactating women are advised to discontinue breastfeeding.
Management of Comorbidities
Patients with comorbidities such as hypertension, diabetes mellitus, or infectious diseases should control their conditions stably prior to treatment to avoid exacerbating risks during medication.
II. Administration Guidelines During Treatment
Dosage and Timing
Take the medicine at a fixed time daily to avoid missing doses or overdosing. If a dose is missed, it can be supplemented if more than 12 hours remain before the next scheduled dose; otherwise, skip the missed dose.
Management of Adverse Reactions
Infection Risk (e.g., fever, cough)
Monitor blood routine regularly and seek medical attention promptly if such symptoms occur.
Bleeding Tendency (e.g., epistaxis, gingival bleeding)
Avoid strenuous exercise and contact with sharp objects. Discontinue the drug and consult a doctor immediately in case of severe bleeding.
Cardiac-Related Symptoms (e.g., palpitations, dizziness)
Undergo regular electrocardiogram (ECG) examinations and report any discomfort to the doctor immediately.
Diet and Lifestyle
Avoid consuming foods that affect drug metabolism, such as grapefruit and star fruit. Quit smoking, limit alcohol intake, and reduce consumption of irritating foods.
III. Monitoring and Follow-Up
Regular Examinations
Recheck blood routine, liver and kidney function, and ECG every 2–4 weeks to evaluate drug tolerance.
Drug Interactions
Avoid concurrent use with anticoagulants (e.g., warfarin), antiplatelet drugs (e.g., aspirin), and potent CYP3A4 inhibitors (e.g., clarithromycin), as these may increase the risk of bleeding or drug toxicity.
IV. Management of Special Circumstances
Hepatic or Renal Dysfunction
Adjust the dosage based on test results. Caution is advised in patients with moderate to severe liver impairment.
Surgery or Invasive Procedures
Discontinue the drug 1–2 weeks in advance, with the specific duration determined by the doctor’s assessment.
In case of severe skin rash, dyspnea, chest pain, or other severe symptoms, discontinue the drug immediately and seek emergency medical care. Maintain close communication with the attending physician during the treatment period to ensure the safety and efficacy of the therapy.
